Loading
A phase 3 trial testing BCD-217 in melanoma, active and no longer recruiting.
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma is a phase 3 interventional study registered as NCT05751928, led by Biocad, and active but no longer recruiting on the registry. Official title: A Randomised Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma. Planned enrolment is 411 participants (actual). The study started in 2023-04-05 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.